Patents Represented by Attorney Olson & Cepuritis, Ltd.
  • Patent number: 7396549
    Abstract: The invention concerns an enzymatic method for making oenological tannins starting with lumps of wood and an enzymatic method for transforming tannins into tannins for wine-making purposes. The inventive method comprises a step which consists in contacting the lumps of wood or tannins with an aqueous solution comprising a composition containing enzymes of the cellulase class. The invention also concerns an enzymatic composition mainly consisting of enzyme of the cellulase class for making oenological tannins, comprising an endocellulase activity, a xylanase activity a ?-mannanase and/or ?-amylase activity.
    Type: Grant
    Filed: March 2, 2001
    Date of Patent: July 8, 2008
    Assignee: ETS. Robert Stiernon, S.A.
    Inventor: Olivier Henry
  • Patent number: 7396669
    Abstract: Isolated mammalian Mus81-Eme endonuclease complexes comprise an Mus81 protein portion and an Eme protein portion. A method of identifying a chemical compound that modulates mammalian cellular response to DNA damage comprises contacting a chemical compound to be tested with a biochemical mixture containing an isolated mammalian Mus81-Eme1 endonuclease complex, a source of magnesium ion, and a suitable DNA substrate; measuring the activity level of mammalian Mus81-Eme endonuclease complex in the mixture; comparing the measured activity level to the activity level of a substantially similar mixture of isolated Mus81-Eme1 endonuclease, magnesium ion, and DNA substrate in the absence of the chemical compound to be tested; and selecting a chemical compound that increases or decreases the endonuclease activity. Isolated mammalian Eme1 and Eme2 proteins derived from humans and murine species and isolated nucleic acids encoding the proteins are also described.
    Type: Grant
    Filed: June 30, 2004
    Date of Patent: July 8, 2008
    Assignee: The Scripps Research Institute
    Inventors: Michael N. Boddy, Veronique Blais, Xiao-Bo Chen, Clare H. McGowan, Pierre-Henri L. Gaillard, Paul R. Russell
  • Patent number: 7389671
    Abstract: A device and method of making same. The device or hydrogen detector has a non-conducting substrate with a metal film capable of absorbing hydrogen to form a stable metal hydride. The metal film is on the threshold of percolation and is connected to mechanism for sensing a change in electrical resistance in response to the presence of hydrogen in contact with the metal film which causes an increase in conductivity.
    Type: Grant
    Filed: November 7, 2006
    Date of Patent: June 24, 2008
    Assignee: UChicago Argonne, LLC
    Inventors: Tao Xu, Michael P. Zach, Zhili Xiao
  • Patent number: 7390190
    Abstract: A combination of a flame arrestor with a reflection suppressor is provided which not only arrests an advancing flame front, but also suppresses or mitigates a reflection wave that is generated by a pressure wave that passes through the combination and continues on to a pipe restriction what generates a reflection wave that proceeds back to the combination. At the combination, the reflection suppressor suppresses and/or mitigates the reflection wave, thereby avoiding a heightened pressure in the combination that could cause a re-ignition and a new flame front and pressure front. The reflection suppressor has a tapered profile that permits a pressure wave to pass along and past the reflection suppressor as it leaves the combination but that impedes and mitigates a returning reflection wave produced by the pressure wave striking a pipe restriction and causing such a returning reflection wave.
    Type: Grant
    Filed: March 13, 2006
    Date of Patent: June 24, 2008
    Assignee: The Protectoseal Company
    Inventor: Dwight E. Brooker
  • Patent number: 7392141
    Abstract: A method of preparing a modified granulocyte colony stimulating factor (G-CSF) protein having reduced immunogenicity relative to human G-CSF comprises the steps of (i) identifying one or more potential T-cell epitopes within the amino acid sequence of human G-CSF (SEQ ID NO: 1); (ii) designing at least one sequence variant of at least one potential T-cell epitope identified in step (i), wherein the sequence variant eliminates or substantially reduces the MHC class II binding activity of the potential T-cell epitope; (iii) preparing, by recombinant DNA techniques, at least one modified G-CSF protein including a sequence variant designed in step (ii); (iv) evaluating at least one modified G-CSF protein prepared in step (iii) for G-CSF activity and immunogenicity; and (v) selecting a modified G-CSF protein evaluated in step (iv) that has substantially the same therapeutic G-CSF biological activity as, but substantially less immunogenicity than, human G-CSF.
    Type: Grant
    Filed: February 5, 2002
    Date of Patent: June 24, 2008
    Assignee: Merck Patent GmbH
    Inventors: Francis J. Carr, Graham Carter, Tim Jones, Stephen Williams
  • Patent number: 7384145
    Abstract: A system and method for obtaining information about the spatial distribution of photoreceptor activity and neural activity in the retina using simultaneously recorded multiple biopotential signals. The information thus gathered is used to assess retinal dysfunction due to trauma or disease. The biopotential signals are recorded from the surface of the eye and head using a plurality of electrodes, including those integral to a contact lens. The biopotential signals are recorded before, during and after the presentation of an optical stimulus to the subject eye. The recorded biopotential signals are then analyzed and interpreted to reveal the distribution of photoreceptor activity and neural activity across the retina. The analysis and interpretation of the biopotential signals is quantitative, and makes use of an electromagnetic model of the subject eye. The subject may be animal or human.
    Type: Grant
    Filed: February 15, 2007
    Date of Patent: June 10, 2008
    Assignee: The Board of Trustees of the University of Illinois
    Inventors: John R. Hetling, Tamas Ban, Safa Rahmani
  • Patent number: 7381795
    Abstract: A modified interferon beta (INF?) is provided, which is less immunogenic than human INF? (SEQ ID NO: 1) when administered to a human in vivo. The modified INF? comprises an amino acid residue sequence that differs from SEQ ID NO: 1 by a substitution at one or more residues of SEQ ID NO: 1. Preferred substitutions are at residues selected from the group consisting of residue 50, 59, 60, 62, 63, 66, 67, 69, 70, 125, 126, 129, 130, 132, 133, and 138. Examples of suitable substitutions include F50A, L57A, I59A, Y60N, M62A, L63A, I66T, F67H, I69A, F70A, Y125A, Y126A, I129A, L130A, Y132S, L133A, Y138H, and Y138A.
    Type: Grant
    Filed: March 15, 2002
    Date of Patent: June 3, 2008
    Assignee: Merck Patent GmbH
    Inventors: Francis J. Carr, Graham Carter, Tim Jones, John Watkins, Matthew Baker
  • Patent number: 7368478
    Abstract: Angiogenesis, tumor growth, and metalloproteinase 2 (MMP2) interaction with integrin-?v?3 are inhibited by an inhibitor compound of formula: wherein G1 and G2 are each independently —NH—C(O)—O—(CH2)v—(C6H4)—X3 ; Y1 and Y2 are each independently —OH or C1-C4 alkoxy; X1 and X2 are each independently halo or C1-C4 alkoxy; X3 is fluoro, nitro, C1-C4 alkyl, C1-C4 alkoxy, or C1-C4 perfluoroalkyl; Z is —C?C—, —C6H4—, cis-CH?CH—, trans-CH?CH—, cis-CH2—CH?CH—CH2—, trans-CH2—CH?CH—CH2—, 1,4-naphthyl, cis-1,3-cyclohexyl, trans-1,3-cyclohexyl, cis-1,4-cyclohexyl, or trans-1,4-cyclohexyl; A is H or a covalent bond; m and n are each 1; t is an integer having a value of 0 or 1; p and r are each 2, and v is 1; with the proviso that when A is H, t is 0, and when A is a covalent bond, t is 1.
    Type: Grant
    Filed: May 24, 2006
    Date of Patent: May 6, 2008
    Assignee: The Scripps Research Institute
    Inventors: Dale L. Boger, David A. Cheresh
  • Patent number: 7369162
    Abstract: An Image sensing apparatus employing a multi-chip system and having a super-parallel circuit structure capable of performing processes such as image processing in real time. A first chip of a first of a first stage has first pixel circuits each having an optical sensor and first processing circuits and arranged in a matrix. A second chip of a second stage has second pixel circuits each having an analog memory for storing analog information from the preceding stage and second processing circuits and arranged in a matrix so as to correspond to the first pixel circuits. In each of the first and the second chip, each of the first and the second processing circuits receives an analog signal from another first and second processing circuit in the vicinity so as to perform first and second analog processing and performs circuit noise compensation by parallel calculation.
    Type: Grant
    Filed: September 3, 2002
    Date of Patent: May 6, 2008
    Assignee: Japan Science and Technology Agency
    Inventors: Tetsuya Yagi, Seiji Kameda
  • Patent number: 7365054
    Abstract: The invention provides methods for treating tumors and tumor metastases in a mammal comprising administering, to a mammal in need of treatment, a therapeutic amount of an antagonist sufficient to inhibit angiogenesis in combination with a therapeutic amount of anti-tumor immunotherapeutic agent, such as a anti-tumor antigen antibody/cytokine fusion protein having a cytokine and a recombinant immunoglobulin polypeptide chain sufficient to elicit a cytokine-specific biological response.
    Type: Grant
    Filed: September 26, 2006
    Date of Patent: April 29, 2008
    Assignees: The Scripps Research Institute, EMD Lexigen Research Center Corp.
    Inventors: Holger N. Lode, Ralph A. Reisfeld, David A. Cheresh, Stephen D. Gillies
  • Patent number: 7360573
    Abstract: Cellular panels may be suspended from head rails through the use of a rigid strip of material positioned with the cellular panel. In order to securely position the rigid strip and cellular panel with respect to the head rail, a securement insert is provided. The securement insert includes a cap securable with the head rail by an interference fit and a slot member including a restricting member extending from the cap.
    Type: Grant
    Filed: March 3, 2005
    Date of Patent: April 22, 2008
    Assignee: Teh Yor Co., Ltd.
    Inventors: Fu-Lai Yu, Chin-Tien Huang
  • Patent number: 7359601
    Abstract: A laser energy delivery device is provided that is suitable for irradiating a body tissue with relatively long wavelength laser energy in the presence of an aqueous liquid without significant absorption of the laser energy by the liquid. The device includes an elongate hollow sheath that has an open aperture at its distal end portion and closed at its proximal end, a laser energy conduit such as an optical fiber or hollow wave guide, within the sheath, the distal end of the conduit being disposed near the open aperture at the distal end portion of the sheath, and the proximal end of the conduit being adapted for connection to a source of long wavelength laser energy. The sheath also includes an inlet port, spaced from the proximal end of the sheath, and adapted to receive and deliver a biologically compatible gas through the sheath to a body tissue site in contact with the open distal end of the sheath.
    Type: Grant
    Filed: December 19, 2003
    Date of Patent: April 15, 2008
    Assignee: Trimedyne, Inc.
    Inventor: Marvin P. Loeb
  • Patent number: 7358009
    Abstract: Lithium metal oxide compounds of nominal formula Li2MO2, in which M represents two or more positively charged metal ions, selected predominantly and preferably from the first row of transition metals are disclosed herein. The Li2MO2 compounds have a layered-type structure, which can be used as positive electrodes for lithium electrochemical cells, or as a precursor for the in-situ electrochemical fabrication of LiMO2 electrodes. The Li2MO2 compounds of the invention may have additional functions in lithium cells, for example, as end-of-discharge indicators, or as negative electrodes for lithium cells.
    Type: Grant
    Filed: February 12, 2003
    Date of Patent: April 15, 2008
    Assignee: UChicago Argonne, LLC
    Inventors: Christopher S. Johnson, Michael M. Thackeray, John T. Vaughey, Arthur J. Kahaian, Jeom-Soo Kim
  • Patent number: 7351272
    Abstract: A method of controlling the size and morphology of powder made by the subsurface injection of a halide vapor into a liquid metal is disclosed. A reaction zone is established and the temperature thereof or the time the powder remains therein is controlled to change powder characteristics.
    Type: Grant
    Filed: September 3, 2003
    Date of Patent: April 1, 2008
    Assignee: International Titanium Powder, LLC
    Inventors: Donn Reynolds Armstrong, Richard Paul Anderson, Lance E. Jacobsen
  • Patent number: D564821
    Type: Grant
    Filed: June 16, 2005
    Date of Patent: March 25, 2008
    Assignee: Teh Yor Co., Ltd.
    Inventors: Fu-Lai Yu, Chin-Tien Huang, Shun-Chi Yu
  • Patent number: D565066
    Type: Grant
    Filed: July 13, 2005
    Date of Patent: March 25, 2008
    Assignee: Seikoh Giken Co., Ltd.
    Inventors: Kunio Yamada, Takehiko Narita
  • Patent number: D566230
    Type: Grant
    Filed: April 30, 2007
    Date of Patent: April 8, 2008
    Assignee: Antelco Pty. Ltd.
    Inventors: Lyall Causby, Robert Sigston, David Bevan Creed
  • Patent number: D570009
    Type: Grant
    Filed: October 25, 2007
    Date of Patent: May 27, 2008
    Assignee: PIAA Corporation
    Inventors: Gen Kani, Yukari Ishiwatari, Hideaki Shimada
  • Patent number: D570675
    Type: Grant
    Filed: January 30, 2007
    Date of Patent: June 10, 2008
    Assignee: Champion Laboratories, Inc.
    Inventors: Jason P. Snider, W. Scott Atteberry
  • Patent number: D571243
    Type: Grant
    Filed: February 12, 2007
    Date of Patent: June 17, 2008
    Assignee: Cateye Co., Ltd.
    Inventor: Yoji Okuda